Characterization of Macrophages and Osteoclasts in the

Osteosarcoma Tumor Microenvironment at Diagnosis: New





OATAO is an open access repository that collects the work of Toulouse 
researchers and makes it freely available over the web where possible 
Any correspondence concerning this service should be sent  
to the repository administrator: tech-oatao@listes-diff.inp-toulouse.fr 



































To cite this version:  
Gomez-Brouchet, Anne and Gilhodes, Julia and Van Acker, 
Nathalie, [et al.] Characterization of Macrophages and Osteoclasts 
in the Osteosarcoma Tumor Microenvironment at Diagnosis: New 
Perspective for Osteosarcoma Treatment? (2021) Cancers, 13 (3). 
ISSN 2072-6694 
Open  Archive  Toulouse  Archive  Ouverte 





Cancers 2021, 13, 423. https://doi.org/10.3390/cancers13030423 www.mdpi.com/journal/cancers 
Article 
Characterization of Macrophages and Osteoclasts in the  
Osteosarcoma Tumor Microenvironment at Diagnosis: New 
Perspective for Osteosarcoma Treatment? 
Anne Gomez-Brouchet 1,*, Julia Gilhodes 2, Nathalie Van Acker 3, Regis Brion 4, Corinne Bouvier 5, Pauline Asse-
mat 6, Nathalie Gaspar 7, Sebastien Aubert 8, Jean-Marc Guinebretiere 9, Beatrice Marie 10, Frederique Larousserie 11, 
Natacha Entz-Werlé 12, Gonzague de Pinieux 13, Eric Mascard 14, Francois Gouin 15, Pierre Brousset 3, Marie-Domi-
nique Tabone 16, Marta Jimenez 17, Marie-Cecile Le Deley 18, Jean-Yves Blay 17, Laurence Brugieres 19,†, Sophie Pi-
perno-Neumann 20,† and Francoise Rédini 4 
1 Department of Pathology, CHU, IUCT-Oncopole, University of Toulouse, Eq19. ONCOSARC CRCT, UMR 
1037 Inserm/UT3, ERL 5294 CNRS, 31059 Toulouse, France 
2 Biostatistics Unit, Institut Claudius Regaud, IUCT-Oncopole, 31059 Toulouse, France; Gilhodes.Julia@iuct-
oncopole.fr 
3 Department of Pathology, CHU, Imag’IN Platform, IUCT-Oncopole, Toulouse 31059, France; 
vanacker.nathalie@iuct-oncopole.fr (N.V.A.); brousset.p@chu-toulouse.fr (P.B.) 
4 Pôle Os—Articulations—Chirurgie Plastique, University of Nantes, INSERM UMR 1238, 44035 Nantes, 
France; regis.brion@univ-nantes.fr (R.B.); francoise.redini@univ-nantes.fr (F.R.) 
5 Department of Pathology, CHU la Timone, 13005 Marseille, France; Corinne.BOUVIER2@ap-hm.fr 
6 Institut de Mécanique des Fluides de Toulouse, UMR 5502 CNRS, INPT, University of Toulouse, 31400 
Toulouse, France; pauline.assemat@imft.fr 
7 Department of Oncology for Child and Adolescents, Gustave Roussy Cancer Center, Paris-Saclay Univer-
sity, 94805 Villejuif, France; Nathalie.GASPAR@gustaveroussy.fr 
8 Department of Pathology, CHRU Lille, 59000 Lille, France; Sebastien.AUBERT@CHRU-LILLE.FR 
9 Department of Pathology, Curie Institut, 75005 Paris, France; jean-marc.guinebretiere@curie.net 
10 Department of Pathology, CHRU Nancy, 54035 Nancy, France; b.marie@chru-nancy.fr 
11 Department of Pathology, AP-HP, Hôpital Cochin, Université Paris Descartes, 75014 Paris, France; frede-
rique.larousserie@aphp.fr 
12 Pediatric Oncology Department CHRU, Hautepierre, 67200 Strasbourg, France; Natacha.entz-werle@chru-
strasbourg.fr 
13 Department of Pathology, CHU, 37000 Tours, France; gonzague.dubouexic@univ-tours.fr 
14 Department of Pediatric Orthopedic Surgery, AP-HP, Necker Hospital, 75015 Paris, France; Eric.mas-
card@wanadoo.fr 
15 Centre Léon-Bérard Lyon, CHU Nantes, Université de Nantes, INSERM UMR 1238, 69008 Lyon, France; 
Francois.GOUIN@lyon.unicancer.fr 
16 Pediatric Oncology Department, Armand Trousseau, APHP, 75012 Paris, France; marie-
dominique.tabone@aphp.fr 
17 Unicancer, Paris, France, Department of Oncology, Centre Leon-Bérard, Claude Bernard University, Lyon 
69008, France; m-jimenez@unicancer.fr (M.J.); jean-yves.blay@lyon.unicancer.fr (J.Y.B.) 
18 Biostatistics Unit, Gustave Roussy Cancer Campus, 94805 Villejuif, France; m-ledeley@o-lambret.fr 
19 Department of Pediatric Oncology, Gustave Roussy, 94805 Villejuif, France; Laurence.BRU-
GIERES@gustaveroussy.fr 
20 Department of Medical Oncology, Institut Curie, 75005 Paris, France; sophie.piperno-neumann@curie.net 
* Correspondence: gomez.anne@chu-toulouse.fr; Tel.: +33-5-31156138 
† These authors contributed equally. 
Simple Summary: Due to the great genetic instability of osteosarcoma (OS), a recurrent molecular 
therapeutic target has not been identified to date. Therefore, characterization of the OS tumor mi-
croenvironment (TME) might offer new therapeutic perspectives. The OS2006 trial, originally de-
signed to evaluate the impact of zoledronic acid (ZA, osteoclast-inhibitor) addition to conventional 
OS-therapies, was ended preliminary due to a negative impact on patient survival. Through retro-
spective biomarker analysis of the unique biological samples collected during the trial, we demon-
strate here that ZA not only acts on harmful osteoclasts but also on protective macrophages, clari-
fying its detrimental effect. By multiplex immunohistochemistry, applied on additional OS biopsies, 
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an important bipotent macrophage-population (CD168+/CD163+), homogenously distributed 
throughout OS tumor areas, was identified. These bipotent cells might play a determining role in 
the evolution of OS and offer a novel therapeutic approach. A clear definition of the macrophage 
populations present at diagnosis could re-enforce therapeutic decisions. 
Abstract: Biological and histopathological techniques identified osteoclasts and macrophages as tar-
gets of zoledronic acid (ZA), a therapeutic agent that was detrimental for patients in the French 
OS2006 trial. Conventional and multiplex immunohistochemistry of microenvironmental and OS 
cells were performed on biopsies of 124 OS2006 patients and 17 surgical (“OSNew”) biopsies re-
spectively. CSF-1R (common osteoclast/macrophage progenitor) and TRAP (osteoclast activity) lev-
els in serum of 108 patients were correlated to response to chemotherapy and to prognosis. TRAP 
levels at surgery and at the end of the protocol were significantly lower in ZA+ than ZA− patients 
(padj = 0.0011; 0.0132). For ZA+-patients, an increase in the CSF-1R level between diagnosis and sur-
gery and a high TRAP level in the serum at biopsy were associated with a better response to chem-
otherapy (p = 0.0091; p = 0.0251). At diagnosis, high CD163+ was associated with good prognosis, 
while low TRAP activity was associated with better overall survival in ZA− patients only. Multiplex 
immunohistochemistry demonstrated remarkable bipotent CD68+/CD163+ macrophages, homoge-
neously distributed throughout OS regions, aside osteoclasts (CD68+/CD163−) mostly residing in 
osteolytic territories and osteoid-matrix-associated CD68−/CD163+ macrophages. We demonstrate 
that ZA not only acts on harmful osteoclasts but also on protective macrophages, and hypothesize 
that the bipotent CD68+/CD163+ macrophages might present novel therapeutic targets. 
Keywords: osteosarcoma; zoledronic acid; osteoclast; macrophage; bipotent macrophage; multiplex 
 
1. Introduction 
Osteosarcoma (OS) is the most common primary malignant bone tumor [1] and has 
a worldwide incidence of one to three cases per million annually with a higher incidence 
in teenagers (0.8–1.1/100,000/year for ages 15–19). Conventional OS is the most common 
histologic subtype (75% of all cases) [1,2]. Microscopically, it is of high grade, highly het-
erogeneous, with cells that produce varying amounts of osteoid/chondroid matrix. Con-
ventional OS are then divided in three major subtypes: osteoblastic (50%), chondroblastic 
(25%) and fibroblastic (25%) OS [3]. OS represents [1] radiographically mixed lesions with 
heterogeneous distribution of lytic and sclerotic territories [4]. Sclerosis is the result of 
tumoral osteoid production, and osteolysis is the result of osteoclastic resorption [4]. The 
high complexity of the OS genome did not allow for the identification of key molecular 
therapeutic targets so far [5–7]. Hence, OS treatment—based on chemotherapy with sur-
gical resection—and survival rates, have not evolved over the past 4 decades. The prog-
nosis remains poor for 25% of OS patients generally presenting metastatic relapses [8–12]. 
New therapies are needed to better control metastatic clones and increase survival. Ther-
apeutic approaches inhibiting the PI3K-mTOR and IGF pathways, might be of interest, as 
shown in in vitro models [13,14], but need yet to be investigated and validated in patients 
with OS. Several phase II clinical trials [15,16] are currently under evaluation for new drug 
efficacy at diagnosis and relapse respectively. Results however are not yet available or 
need further investigation. 
The pivotal role played by the bone Tumor Micro-Environment (TME) has been sug-
gested for many years in OS [17–19]. The bone microenvironment is very complex, with a 
finely balanced interplay between osteoblasts, osteoclasts, chondrocytes, mesenchymal 
stem/progenitor cells, hematopoietic cells, endothelial cells, and others [20]. The process 
of bone formation by osteoblasts and bone resorption by osteoclasts is regulated by the 
biological activity of various factors required for bone homeostasis. An instability in this 
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process may induce the formation of abnormal progenitors and thus result in an imbal-
ance between the demand of progenitor cells in periods of intensive bone formation and 
remodeling [20]. Osteoclastic cells (OCs) have been reported to be associated with a poorer 
prognosis in the pathogenesis of OS [19]. Preclinical studies from our group showed that 
zoledronic acid (ZA)—an inhibitor of the OC function—suppressed lung metastasis and 
prolonged survival of OS-bearing mice [21], and that ZA in combination with a stimulator 
of macrophage activity enhanced primary tumor regression in pre-clinical xenogeneic and 
syngeneic mice models [22]. Based on the assumption of the existence of a vicious cycle 
between tumor cell proliferation and bone degradation by OCs [19,20,23], the French 
OS2006 trial [11] was developed, aiming at evaluating the impact of the addition of ZA—
an inhibitor of the OC function—to conventional therapies (surgery and chemotherapy) 
on patient survival. The study showed that ZA did not improve the outcome and could 
even be detrimental on survival [11,24]. Initially, the OS2006 trial was not designed to 
understand the role of the TME in the biology of OS. The unique sample collection (in-
cluding serum collection over time and biopsy collection at diagnosis) collected simulta-
neously, served to analyze the role of the TME cells in this exploratory study.  
As in most sarcomas [24], the OS immune-TME mainly comprises TAM [25,26], den-
dritic cells, myeloid cells, OCs and different amounts of T-lymphocytes [25]. Recent stud-
ies revealed that an infiltrate rich in TAM induce immunosuppression, responsible for the 
inefficacy of lymphocyte-targeted therapies [24,27]. Previously, we have shown that a low 
amount of CD8+ T-lymphocytes, at diagnosis, appeared to be associated with increased 
OS metastasis in accordance with findings of Zhang and colleagues [26,28]. The beneficial 
role of macrophage infiltration has been repeatedly reported in OS patients [26,29–31]. 
Two main subsets of macrophages are usually taken into consideration, the pro-inflam-
matory M1 type and the anti-inflammatory pro-tumoral M2 type [29,32]. The polarization 
and infiltration of these two macrophage subtypes dynamically change [32], depending 
not only on the cytokines secreted by the tumor cells and/or the microenvironment’s im-
mune cells but also on numerous other factors including genetic drivers of disease, host 
specific considerations (lifestyle, age, menopause status), as well as immune-related basis 
for disease [33,34]. Analysis of the transcriptome indicate that TAMs have a mixed phe-
notype expressing both M1 and M2 markers [35]. In general, TAM from established tu-
mors have properties of M2-activated cells, enhancing epithelial-mesenchymal transition 
(EMT), helping cancer progression and metastasis [34,36]. In an in vitro osteosarcoma 
study, Zhou and colleagues demonstrated that M2 polarization of TAMs promoted pul-
monary metastasis and that the STAT3/6 family and the nuclear receptor PPAR-γ were 
the transcription factors that translate signals and polarize macrophages into the M2 phe-
notype [37].  
Despite the continuous evolution with regards to the in situ identification of M1- and 
M2-macrophages [32,38], no clear consensus is defined for the use of tissue-markers that 
formally differentiate M1 macrophages from M2. In some studies, CD68 is considered to 
be a pan-macrophage marker, in others it is stated to be an M1-polarized macrophage 
marker. In the light of bone tissue and OS, CD68 can be considered as a marker of macro-
phages and of OCs [39], a type of cells that plays a crucial role in bone remodeling [40]. 
On the other hand, CD163 is widely used as a macrophage marker [41], enabling the study 
of the so-called M2-type macrophages. In tumoral bone tissue, different types of resident 
macrophages can be found, with or without osteoclastic activity [42,43]. It is known that 
the monocyte/macrophage lineage gives rise to OC by the action of macrophage colony 
stimulating factor (M-CSF or CSF-1) and receptor activator of nuclear factor-kB ligand 
(RANKL) [44]. Recently, Xiao Y et al. [45] showed that monocytes/macrophages, OCs, and 
dendritic cells shared a common progenitor that gives rise to a bipotent macrophage/OC 
progenitor. Previously, we demonstrated that only CD163+ TAM infiltration was associ-
ated with a better prognosis in OS [26], and that CD68+ macrophages could oppose this 
positive effect on OS patient prognosis [26,29–31], in contrast to what happens in soft tis-
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sue tumors. Both in vivo and in vitro co-culture studies from our group and others respec-
tively have shown that the OCs and macrophages play important roles in the develop-
ment and progression of OS and metastases [22,46]. Taken together, these data confirm 
the relevance of studying CD68+ OCs and CD163+ macrophages in the TME of OS rather 
than studying M1 and M2 types of macrophages. Thus, we hypothesize that not only 
CD68+ OCs, but also CD163+ macrophages and even their progenitors play a crucial role 
in patient prognosis and that they could all represent a ZA target, and thus switching the 
ZA expected benefits into deleterious effects. 
In order to clarify the respective roles of OCs and macrophages in the complex TME 
of OS and their involvement in the detrimental effect of zoledronic acid (ZA) treatment 
observed in the OS2006 trial [11], we combined two strategies: (1) Conventional and mul-
tiplex fluorescence immunohistochemistry were performed on biopsies of 124 OS2006 pa-
tients (included in a Tissue Micro Array, TMA) and 17 surgical “OSNew” biopsies respec-
tively. The multiplex immunofluorescence allowed us to study the spatial distribution of 
CD68+ OCs, CD163+ macrophages, cytotoxic CD8+ T-cells and SATB2+ osteosarcoma cells 
by digital analysis; (2) Serum biomarker analysis was performed for 108 patients at diag-
nosis and all along the treatment of the OS2006 trial [11] and was correlated to the re-
sponse of chemotherapy and to prognosis. The tartrate-resistant acid phosphatase (TRAP) 
activity allowed us to study OC activity [47,48]—related to the CD68+ OC biomarker—
[39] and colony-stimulating factor 1 receptor (CSF-1R) enabled us to study progenitors of 
both CD68+ OCs and CD163+ macrophages [45]. 
Three important results stand out from our study: (1) The multiplex immunofluores-
cence digital analysis allowed us to identify a double CD68+/CD163+ positive TAM pop-
ulation, with unknown polarization and probably high plasticity in response to the com-
plex interactions with the other cells of the TME, OS cells and which most likely has an 
impact on patient response to treatment; (2) CD68−/CD163+ macrophages, associated to a 
good prognosis, are primarily observed in osteoid-rich tumor regions, the predominant 
morphological OS type, and exert opposite effects to CD68+/CD163− OCs found predom-
inantly in osteolytic regions; (3) ZA inhibits not only OCs but more importantly CD163+ 
macrophages initially associated to a good prognosis, explaining the detrimental effect of 
ZA in the OS2006 trial. Our data highlight the importance of studying the balance between 
OCs and macrophages in the development of OS and in treatment efficacy. A clear defi-
nition of the macrophage populations present at diagnosis could re-enforce therapeutic 
decisions. 
2. Results 
2.1. Description of the OS2006 Patient Population 
Patient and tumor characteristics, treatment and outcomes are described in Table S1 
for the entire initial OS2006 cohort with available tissue microarrays (n = 124) and in Table 
1 for the 108 (out of 124) patients for whom additional serum assays were performed and 
thus included in this study. Thirty-nine of them (36.1%) received ZA (ZA+) and the re-
maining 69 patients received chemotherapy only (ZA−; randomized or not). We investi-
gated the representability of the included population. No statistical difference was ob-
served between the excluded and included patients in the present study in terms of clini-
cal parameters. Only the chemotherapy response was better in the ZA+ subgroup whereas 
the overall survival remained the same. 
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Table 1. Demographic, clinical and histological data of the OS2006 patient cohort included in the 
present study (n = 108). 
OS2006 Patient Data 
Included Patients 
Total ZA− ZA+ 
p 
n = 108 n = 69 n = 39 
Age     
Med (Range) 15 (5–50) 16 (5–48) 15 (8–50) 0.7907 
<18y 72 (66.7%) 48 (69.6%) 24 (61.5%) 0.3954 
≥18y 36 (33.3%) 21 (30.4%) 15 (38.5%)  
Sex     
Male 65 (60.2%) 42 (60.9%) 23 (59.0%) 0.8468 
Female 43 (39.8%) 27 (39.1%) 16 (41.0%)  
Limb vs Axial     
Axial 12 (11.1%) 7 (10,1%) 5 (12.8%) 0.7534 
Limb 96 (88.9%) 62 (89.9%) 34 (87.2%)  
Conventional osteosarcoma     
Chondroblastic 28 (25.9%) 20 (29.0%) 8 (20.5%) 0.6858 
Osteoblastic 68 (63.0%) 42 (60.9%) 26 (66.7%)  
Fibroblastic 6 (5.6%) 3 (4.3%) 3 (7.7%)  
Other 6 (5.6%) 4 (5.8%) 2 (5.1%)  
Meta vs non meta     
Localized 86 (79.6%) 55 (79.7%) 31 (79.5%) 0.9780 
Metastases 22 (20.4%) 14 (20.3%) 8 (20.5%)  
Chemotherapy     
API-AI 13 (12.0%) 6 (8.7%) 7 (17.9%) 0.2180 
MTX 95 (88.0%) 63 (91.3%) 32 (82.1%)  
Chemotherapy response     
GR 67 (65.0%) 38 (57.6%) 29 (78.4%) 0.0336 
PR 36 (35.0%) 28 (42.4%) 8 (21.6%)  
Missing 5 3 2  
2.2. Immunohistochemical Analyses of Macrophage and Osteoclast Cell Populations in OS2006 
Cohort 
Classic immunohistochemistry of cytotoxic T-lymphocytes (CD8+) and macro-
phage/osteoclastic populations (CD163+/CD68+) revealed low presence of CD8+ cells (me-
dian 1%) and predominant presence of CD163+ macrophages (median 40%) over CD68+ 
OCs (median 20%) (Table 2). No significant difference was noticed for these 3 markers in 
the studied population (ZA+, ZA−). 
2.3. Fluorescence Multiplex Digital Analysis of the Spatial Heterogeneity of Tumor 
Microenvironmental Cells in “OSNew” Cohort 
The TME cell population (CD8, CD163 and/or CD68) of the “OSNew” surgical biop-
sies (n = 17) was analyzed in 287 tumor regions (total of 1260.3mm2), being morphologi-
cally classified into osteolytic (OL, 83.6%, 1118.3mm2) and osteoid matrix rich (OM, 16.2%, 
142.0mm2) regions. Five biopsies did not contain OL tumor regions (29.4%), 8 biopsies did 
not contain OM tumor regions (47.1%). The discrepancy between the number of OM and 
OL regions is related to the surgical biopsy procedure applied for OS patients, which aims 
at including cellular rich areas (OL). 
SATB2 (Figure 1, green) nuclear density, visualizing osteoblastic cells, differentiated 
areas showing OM (mean 427.1/mm2) and OL (mean 867.0/mm2) morphological charac-
teristics. OM regions are characterized by an abundant bone matrix and low cellularity, 
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whereas OL areas show high cellular density with nearly absent matrix (Figure 1A and 
Figure 1B respectively) and often cystic formations. 
The automated cell count revealed that CD8+ T-cells are scarce and account for 0.59% 
(mean) of the overall studied cell population, thus confirming the findings of the IHC 
analysis. CD8+ cells are however mainly present in osteolytic regions (OL: mean 0.70%; 
OM: mean 0.23%). CD68+ (Figure 1, purple) and CD163+ (Figure 1, red) cells seem to be 
differentially distributed in OM and OL regions. In OM regions (Figure 1A), the TME cell 
population is predominated by the macrophages of the CD68−/CD163+ subtype (mean 
12.92%). OCs (CD68+/CD163−) (mean 4.29%) and double positive CD68+/CD163+ macro-
phages (mean 5.48%) are in minority (Figure 1, A1-A2-A3). In OL regions, however ((Fig-
ure 1B), a macrophage phenotype switch occurs resulting in a homogenous population 
consisting of CD68−/CD163+ macrophages (mean 10.28%) along with an important OC 
(CD68+/CD163−) (mean 7.46%) and double positive (CD68+/CD163+) macrophage (mean 
9.26%) recruitment (Figure 1, B1-B2-B3). 
 
Figure 1. Macrophage and osteoclast population studied by multiplex immunohistochemistry. Histological and immuno-
fluorescent representation of osteoid matrix forming (A, OM), osteolytic (B, OL) tumor regions in OS. (A) and (B) Repre-
sentative region demonstrated with Hematoxylin and eosin staining (H&E). The histograms represent the percentage of 
the different cell populations in OM (left) and OL (right) regions: CD68+CD163+ (dashed white/red), CD68−CD163+ (red), 
CD68+CD163− (purple). (A) Histological and immunofluorescent (A1–A3) representation of cell populations present in 
OM tumor regions of OS. These regions are characterized by low SATB2-density (A1–A3, green) and a predominant 
CD163+ macrophage population (A1–A3, red) (CD68+ osteoclasts: purple). (B) Histological and immunofluorescent (B1–
B3) representation of cell populations present in OL tumor regions of OS. These regions are characterized by high SATB2-
density (B1–B3, green) and a predominant CD163+ macrophage population (B1–B3, red) and an important osteoclast-
infiltrate (B1–B3, purple). Hoechst or hematoxylin nuclear counterstain: Blue. Scale bar A1-A2-A3, B1-B2-B3: 100 µm. 
2.4. Temporal Serum Assay Analysis of Macrophage and Osteoclast Activities (OS2006 Cohort) 
A two-way repeated measure ANOVA was run on the 108 patients to determine if 
there were differences in TRAP activity and CSF-1R concentration over time and treat-
ment. The results showed statistically significant differences in mean TRAP and CSF-1R 
over time (p < 0.005). The interaction term between treatment and time was significantly 
associated with TRAP only (p < 0.005). The median serum level of CSF-1R and TRAP at 
Cancers 2021, 13, 423 7 of 19 
 
 
diagnosis was respectively 619.5 ng/ml and 9.7 U/L, with no significant difference between 
ZA+ or ZA− patients (Table 2, Figure 2). TRAP levels decreased during treatment in the 
entire selected cohort. Additionally, TRAP levels were significantly lower in the group of 
ZA+ patients compared to the group of ZA− patients at surgery (padj = 0.0011) and at the 
end of the protocol (padj = 0.0132). On the contrary, CSF-1R levels increased during treat-
ment with no significant difference between ZA− and ZA+ patients (Table 2, Figure 2). 
Table 2. A: Immunohistochemical analysis of macrophage, osteoclast and T-lymphocyte markers; B. serum levels of the 
OS2006 patients (n = 108). Bonferroni’s adjustments were made to account for multiple testing. 
 Included Patients Total ZA- ZA+ 
padj 
  n = 108 n = 69 n = 39 
A.IHC     
 CD8 (%)     
  Med (Range) 1 (0–60) 1 (0–60) 1 (0–30) 1.0000 
  Missing 12 9 3  
 CD163 (%)     
  Med (Range) 40 (0–80) 40 (0–80) 40 (0–80) 1.0000 
  Missing 27 18 9  
 CD68 (%)     
  Med (Range) 20 (0–80) 20 (0–80) 20 (0–80) 1.0000 
  Missing 12 7 5  
B.Serum levels     
At diagnosis     
 CSF-1R (ng/mL)     
  Med (Range) 619.5 (159.0–1359.5) 582.0 (159.0–1293.7) 635.3 (175.7–1359.5) 1.0000 
  Missing 4 2 2  
 TRAP (U/L)     
  Med (Range) 9.7 (2.2–48.5) 9.2 (2.2–27.5) 11.1 (2.2–48.5) 1.0000 
  Missing 3 1 2  
At surgery     
 CSF-1R (ng/mL)     
  Med (Range) 683.1 (150.8–2262.1) 619.2 (150.8–2034.8) 854.1 (213.6–2262.1) 1.0000 
  Missing 38 26 12  
 TRAP (U/L)     
  Med (Range) 6.9 (0.5–24.3) 7.6 (3.5–24.3) 5.1 (0.5–9.6) 0.0011 
  Missing 41 27 14  
At the end of treatment     
 CSF-1R (ng/mL)     
  Med (Range) 716.9 (146.9–2714.5) 676.3 (146.9–2714.5) 831.8 (296.1–1988.1) 1.0000 
  Missing 34 22 12  
 TRAP (U/L)     
  Med (Range) 6.5 (0.6–23.3) 7.0 (2.1–23.3) 3.7 (0.6–11.2) 0.0132 
  Missing 36 24 12  
One year after the end of treatment     
 CSF-1R (ng/mL)     
  Med (Range) 518.7 (244.1–1788.4) 499.6 (244.1–1788.4) 615.9 (261.6–1452.4) 1.0000 
  Missing 55 34 21  
 TRAP (U/L)     
  Med (Range) 6.2 (0.9–26.0) 6.4 (2.2–26.0) 5.5 (0.9–13.1) 1.0000 
  Missing 57 34 23  




Figure 2. CSF-1R and TRAP serum levels over time for patients who received (ZA+) or not (ZA−) zoledronic acid. 
2.5. Biomarkers (Immunohistochemical and Serum Assays Analyses) Associated with Response 
to Chemotherapy in the ZA+ versus ZA− Patient Groups (OS2006 Cohort) 
No statistical association was found between biomarkers and response to chemother-
apy in the overall population (Figure 3). Exploratory subgroup analyses showed that in 
the group of patients treated with chemotherapy only, CD163+ staining seemed associated 
with a good response to chemotherapy (p = 0.0148) (Figure 3A, middle panel). On the other 
hand, in the ZA+ subgroup, increase of CSF-1R (Figure 3B) between diagnosis and surgery 
and a high TRAP (Figure 3C) level in serum at biopsy were both associated with a better 
response to chemotherapy (p = 0.0091 and p = 0.0251 respectively). The decrease of CSF-
1R (Figure 3B, right panel) between diagnosis and surgery tends to be associated to a 
poorer response. Nevertheless, these findings were not significant after adjusting for mul-
tiple testing. 
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Figure 3. Correlation of biomarkers with response to chemotherapy for patients who received (ZA+) or not (ZA−) 
zoledronic acid. (A) Representation of response to chemotherapy (GR: good responders; PR: poor responders) in relation 
to immunohistochemical analysis (% of cells positive) of CD8 (left panel), CD163 (middle panel) and CD68 (right panel). 
(B) Representation of response to chemotherapy (GR: good responders; PR: poor responders) in relation to serum analysis 
of CSFR-1 at diagnosis (left panel), surgery (middle panel) and the difference of CSF-1R levels between diagnosis and 
surgery (right panel). (C) Representation of response to chemotherapy (GR: good responders; PR: poor responders) in 
relation to serum analysis of TRAP at diagnosis (left panel), surgery (middle panel) and the difference of TRAP levels 
between diagnosis and surgery (right panel). 
2.6. Clinical Parameters and Biomarkers Associated with Survival in Patients and Subgroup 
Analyses 
After a median follow-up of 63 months (95%CI [58; 67]), thirty-four patients (31.5%) 
had died. The 5-year overall survival rate was estimated at 72.3% (95%CI [62.0–80.3]). 
Metastatic progression-free survival (MPFS) occurred in 37.0% of patients (40/108) and the 
five-year MPFS rate was estimated to 61.2% (95%CI [51.6; 69.5]). Univariable analyses for 
Overall Survival and MPFS are presented in Table 3. In the overall population, CD163 was 
the only biomarker significantly associated with better Overall Survival and MPFS (p = 
0.011 and p = 0.019 respectively). Multivariable analyses presented in Table S2 show that 
these results do not remain significant after adjusting on prognostic clinical factors (histo-
logical subtype, presence of metastases at diagnosis and chemotherapy response).  
In exploratory subgroup analysis (univariable analysis, Table 3), we have observed 
that a high level of CD163 and a low rate of TRAP at diagnosis were associated with a 
better overall survival among ZA- patients (p = 0.026 and p = 0.017 respectively) and a 
trend was observed for metastatic progression-free survival (MPFS) (p = 0.081 and p = 
0.051). In the group of patients treated with ZA (ZA+), no statistical correlation with Over-
all Survival or MPFS was noticed, nevertheless the magnitude of CD163 differences in 
prognosis was similar between the two treatment arms. For illustrative purposes, we pre-
sent in Figure 4 the Kaplan Meier curves for Overall Survival and MPFS according to 
CD163 and TRAP levels with an arbitrary cut-off at the median. 
Table 3. Univariable analyses of biomarkers associated with overall survival and metastatic progression-free survival and 
exploratory subgroup analyses according to the treatment (n = 108). 
Biomarker Overall Survival 
  All ZA- ZA+ 
  HR [95%CI] p HR [95%CI] p HR [95%CI] p 
CD8 1 [0.7; 1.6] 0.844 1.1 [0.7; 1.7] 0.61 0 [0; 4.6] 0.077 
CD163 0.8 [0.7; 1] 0.011 0.8 [0.7; 1] 0.026 0.8 [0.7; 1.1] 0.184 
CD68 0.9 [0.7; 1] 0.075 0.8 [0.7; 1] 0.054 1 [0.7; 1.3] 0.894 
CSF-1R 1 [0.9; 1.2] 0.926 1 [0.8; 1.2] 0.96 1 [0.8; 1.3] 0.927 
TRAP 1 [1; 1.1] 0.192 1.1 [1; 1.2] 0.017 1 [0.9; 1.1] 0.706 
 Metastatic progression free survival 
 All ZA- ZA+ 
 HR [95%CI] p HR [95%CI] p HR [95%CI] p 
CD8 1.1 [0.7; 1.7] 0.807 1.2 [0.7; 1.9] 0.52 0.7 [0.2; 2.7] 0.609 
CD163 0.9 [0.8; 1] 0.019 0.9 [0.7; 1] 0.081 0.8 [0.7; 1.1] 0.131 
CD68 0.9 [0.8; 1] 0.147 0.9 [0.8; 1.1] 0.183 0.9 [0.7; 1.2] 0.557 
CSF-1R 1 [0.9; 1.2] 0.514 1.1 [0.9; 1.3] 0.305 1 [0.8; 1.2] 0.887 
TRAP 1 [1; 1.1] 0.214 1.1 [1; 1.1] 0.051 1 [0.9; 1.1] 0.888 




Figure 4. Kaplan-Meier curves according to CD163 and TRAP levels in the overall population (left panel), and in ZA− 
(middle panel) and ZA+ (right panel) groups for overall survival (A) and metastatic progression-free survival (B). 
3. Discussion 
The goal of the present study was to try to decipher the spatial distribution of OC 
and macrophage cell populations in the complex microenvironment of OS and to identify 
the targets of Zoledronic Acid (ZA) observed to be harmful for patients during the French 
OS2006 clinical trial. 
To better understand the role of Tissue Associated Macrophages in OS, we developed 
a multiplex multi-target digital analysis of the TME (CD68, CD163, CD8) in relation to 
bone-formation (SATB2) in “OSNew” biopsies, a strategy that has never been reported 
before. With this approach, we demonstrated that CD68+ and CD163+ cells appeared dif-
ferentially distributed throughout morphologically distinct OS tumor regions - cellular 
rich osteolytic (OL) tumor regions and osteoid-matrix (OM) forming tumor regions poor 
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in cellularity - supporting the hypothesis that these two cell types might exert different 
biological activities during OS development. Multiplex immunohistochemistry allowed 
us to identify three macrophage-like phenotypes: CD68−/CD163+, CD68+/CD163− and a 
double positive CD68+/CD163+ TAM. For the first time, we clearly show that CD68-
/CD163+ macrophage dominate in OM tumor regions, over other macrophage pheno-
types. In OL regions, we found a homogenous representation of these TAMs along with 
double labelled CD68+/CD163+ macrophages and CD68+/CD163− OCs. We issued the hy-
pothesis that both CD68+/CD163− and CD68−/CD163+ macrophage subtypes might have, 
in the context of OS, opposite functions, and that the double CD68+/CD163+ subgroup 
might represent a group of bipotent macrophages with high plasticity and undefined po-
larization, waiting to switch to the CD68+/CD163− subtype or polarize to a CD68−/CD163+ 
macrophage variant in response to the different OS and TME stimuli [20,45]. When look-
ing at the global macrophage cell population counted in the OM and OL regions of “OS-
New” biopsies, an equivalent number of CD68−/CD163+, CD68+/CD163− and 
CD163+/CD68+ macrophage subtypes was observed. The discrepancy found with soft tis-
sue sarcomas [24], in which CD163+ macrophages dominate over CD68+ macrophages, 
could be explained by the fact that CD68 is not only a macrophage-marker, but also, in 
the context of bone tissue, a marker of osteoclastic cells. Therefore, OCs increase the ob-
served value of the CD68-marker in osteosarcoma. Another bias might come from the fact 
that biopsies are preferentially performed in OL regions (with higher cellularity), reduc-
ing the OM tumor region analyzed in this study (16%). In the same way, the micro-biop-
sies for the TMA used for conventional IHC were collected in these OL cellular OS regions.  
In clinical practice, the determination of the M1/M2 ratio appears a higher biologi-
cally relevant indicator to cancer prognosis compared to general TAM cell counts, with a 
high M1/M2 ratio relating to a better outcome for the patient [38]. However, considerable 
controversy exists over the in situ visualization of M1 and M2 macrophages. No clear con-
sensus has been reached leading to inter-study disagreement. In addition, in the context 
of bone, the TME is even more complex to study due to the additional involvement of 
bone remodeling cells. The CD68+ cells stated to be M1-polarized macrophages in soft 
tissues, also represent in bone and OS, the osteoclastic cells [39] of the bone remodeling 
[40]. An instability in this process can lead to tumor development depending on the bone 
microenvironmental stimuli and M1/M2 distinction is even more complex to untangle 
[20]. That’s why we focused our study on the CD68+/CD163−, CD68−/CD163+, and 
CD68+/CD163+ cells to highlight the interaction between those cell populations, and their 
role in bone formation or resorption and effect of treatment. New multiplex immunohisto-
chemical strategies could be developed to improve the ability to study macrophage polar-
ization in relation to OCs, and their ratio in OS development and progression. This ap-
proach could become indispensable at the individual level to better define therapeutic 
strategies [30]. 
To enhance our understanding of the deleterious effect of ZA treatment on patient 
prognosis in the OS2006 trial, serum biomarker analysis was performed at diagnosis, be-
fore surgery +/− after 4 injections of ZA, after chemotherapy, one year after the end of 
treatment. Two key biomarkers were analyzed: CSF-1R as a biomarker for common pro-
genitors of OCs and macrophages, and TRAP as an OC-activity biomarker. One biopsy 
was taken from each patient at diagnosis for subsequent conventional immunohistochem-
ical studies of the TME cells (CD68, CD163, CD8). All data were correlated to the response 
to chemotherapy and overall and metastatic progression free survival. We showed that 
TRAP levels decrease significantly during ZA treatment (after pre-operative treatment 
and at the end of the treatment) as compared to the values obtained at diagnosis and one 
year after the end of treatment. This result is in accordance with the diminution of OC 
activity under zometa® treatment, validating for the first time in a trial the biological ac-
tivity of ZA on OC activity in OS patients. We also demonstrate the reversible effects of 
ZA on bone degradation after stopping its administration, confirming the preclinical data 
previously published [49,50]. The negative regulation of OS progression by OCs, reported 
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by Akiyama et al [51] and Ory et al [21] in murine models, is confirmed as well for patients 
randomized in the ZA group. A high TRAP serum level at diagnosis is significantly asso-
ciated with a better response to chemotherapy in ZA+ patients (and not in ZA− patients), 
suggesting that by decreasing OC function, patients defense to OS tumor evolvement sig-
nificantly ameliorates when receiving chemotherapy in combination with ZA. This result 
is reinforced by the fact that a low rate of TRAP at diagnosis associates to a better overall 
survival of ZA− patients. 
Immunohistochemical analysis of the biopsies of the OS2006 trial at diagnosis re-
vealed that the presence of a high CD163+ macrophage proportion may be related to a 
better response to chemotherapy for patients who did not receive ZA and thus resulting 
in a better prognosis for the patient (Overall Survival and MPFS) [26]. In the group of ZA+ 
patients, the association between CD163 staining and prognosis was no longer observed. 
This might be related to a lack on statistical power of the studied group, nevertheless this 
supports our hypothesis that should be verified in a larger cohort. In the ZA+ subgroup, 
we also showed that an increase of CSF-1R between diagnosis and surgery was associated 
with a better response to chemotherapy, and conversely, a decrease of CSF-1R between 
diagnosis and surgery tends to be associated to a poorer response. We suggest thus that, 
in poor responder patients, ZA acts on CD163+ macrophages, cancelling their reported 
protective effect [26,29,30]. ZA might also act on the CD68+/CD163+ bipotent cells, by in-
ducing deleterious polarization, an interesting hypothesis that should be verified in pre-
clinical co-cultures [14,46], and ideally verified in a prospective clinical study. In good 
responder patients however, the increase of CSF-1R levels could indicate a favorable acti-
vation of macrophage progenitors and thus anti-tumoral activity. These findings reinforce 
our hypothesis that not only OCs, but also macrophages represent a target for bisphos-
phonates in OS, as already suggested for breast cancer by Junankanar et al [52], maybe 
through ZA effect on bipotent cells. 
From a therapeutic point of view, our finding that CD68-/CD163+ macrophages - as-
sociated to a better prognosis and better response to chemotherapy - are targeted by 
zoledronic acid (ZA) clarifies the bad results obtained in the OS2006 trial [11]. In addition, 
their predominant presence in osteoid-matrix forming tumor regions – the most frequent 
type of OS – indicates that administration of ZA is not the best therapeutic strategy. Even 
if the therapeutic value of a bisphosphonate or anti-RANKL antibody treatment is limited 
in OS, these drugs have proven their value in the treatment of osteolytic metastasis [17,51] 
and could be further proposed to the rare cases presenting highly osteolytic OS, charac-
terized by high TRAP level in serum at diagnosis. Levels of the circulating RANKL 
marker, considered to be the most accurate marker for the evaluation of metastatic bone 
response [53], could then be useful in assessing the efficacy of such treatments in OS. The 
predominant role of macrophages and OCs in the OS tumor microenvironment along with 
the low presence of cytotoxic T-lymphocytes reinforce the idea that an immunosuppres-
sive environment is created [54]. This opens the possibility to introduce immunomodula-
tion through macrophages as potential therapeutic targets [12,15,22,24] or to use macro-
phage-related immune-checkpoint inhibitors. Other combined therapies acting on the 
mTOR [5,13] or STAT3 [34,37] pathways, in combination with macrophage immunomod-
ulators could be considered to abolish acquired resistance and increase the effectiveness 
of therapies. 
4. Materials and Methods  
4.1. OS 2006 Patients and Tumor Characteristics 
All the patients with localized/metastatic high-grade osteosarcoma were prospec-
tively enrolled in a national OS2006 study (NCT00470223) that included a randomized 
phase-3 trial [11]. They all had biopsies at diagnosis, then 12–13 weeks of pre-chemother-
apy, followed by an excision of the primary tumor. Post-operative chemotherapy was 
adapted to the histological response and risk factors. Patients included in the trial were 
Cancers 2021, 13, 423 13 of 19 
 
 
randomized to receive (ZA+) or not (ZA−) zoledronic acid (4 injections before surgery and 
6 after), in association with chemotherapy.  
Biological studies (immunohistochemistry and serum assays) were conducted in par-
allel with the therapeutic protocol approved for the OS2006 trial. Specific informed con-
sent for tumor samples was obtained from the patients or their parents or guardians if 
patients were under the age of 18 upon enrolment as described in the OS2006 protocol 
[11]. 
4.2. OS 2006 Tissue Microarray  
Tissue microarrays (TMA) were prepared as previously described [26] and used for 
immunohistochemical biomarker analysis (CD8, CD163, CD68). The TMAs were con-
structed with 124 patient samples and were stored at the certified NF 96–900 cancer bi-
obank of Toulouse (BB-0033-00014) where the immunohistochemistry study was con-
ducted. In accordance with French law, the biobank cancer collection was declared to the 
Ministry of Higher Education and Research (DC-2008-463) and a transfer agreement was 
obtained (AC-2013-1955) after approval by the ethics committee. All patient records and 
information were anonymized and de-identified prior to analysis.  
For the 108/124 OS2006 patients, the CSF-1R and TRAP biomarkers analysis was ad-
ditionally performed on serum samples collected at four different time points: diagnosis, 
surgery, end of treatment and one year after the end of the treatment.  
4.3. ‘OSNew’ Sample Collection (Toulouse Cohort) 
To complete our exploration we used 17 “OSNew” surgical biopsies coming from the 
OS Toulouse collection, also stored at the certified NF 96–900 cancer biobank of Toulouse 
(BB-0033-00014). We used these new samples to get a better representation of the hetero-
geneity of OS tumors, because fragments obtained were larger than after core biopsies 
and larger than tissue included in TMAs. Informed consent was obtained from all patients 
and the use of the biological specimens was approved by the local institutional review 
board.  
4.4. Immunohistochemistry 
Automated classical immunohistochemical (IHC) stains were performed using the 
Discovery ULTRA (Roche, Ventana Medical Systems, Innovation Park Drive, Tucson, AZ 
USA). After dewaxing, tissue slides were heat pre-treated using a CC1 (pH8) buffer 
(05424569001, Roche) for CD163 (64 minutes) and CD8 (32 minutes) IHC. Enzymatic pre-
treatment was required for CD68 IHC using Protease 1 for 4 minutes at 37°C (05266688001, 
Roche). The slides were blocked for endogenous peroxidase activity using the CM inhib-
itor (32 minutes at 37 °C) (Roche). The primary ready-to use CD68 (clone PGM1, Agilent 
Technologies, Santa Clara, CA,  USA), CD163 (clone MRQ-26, Roche), CD8 (clone SP57, 
Roche), were incubated for 20 minutes, 32 minutes and 20 minutes respectively, at 36 °C. 
Targets were then linked using the OmniMap anti-rabbit (05269679001, Roche, Tucson, 
AZ, USA) and OmniMap anti-mouse (05269652001, Roche) HRP conjugated secondary 
antibodies. Visualization of the various targets was finally established using the Chromo-
Map DAB detection kit (05266645001, Roche). The tissue slides were counterstained using 
hematoxylin (05277965001, Roche) for 8 minutes followed by post-coloration using the 
Bluing reagent for 4 minutes at room temperature (05266769001, Roche). The slides were 
then dehydrated (ethanol and xylene) and mounted using xylene-based mounting. 
Immunoreactivity was considered positive if detected in >1% of cells per core of 
1mm, irrespective of staining intensity for CD68 (pre-osteoclastic and mature osteoclastic 
cells -multinucleated cells-), CD163 (macrophages), CD8 (cytotoxic T-lymphocytes). Ton-
sils and lymphoid nodes were used as positive controls for all the tested antibodies.  
4.5. Immunofluorescence Multiplex Staining 
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 To further explore the tumor microenvironment (TME), we visualized CD8+ T-cells, 
CD163+ macrophages, and the CD68+ osteoclastic cells in relation to SATB2+ osteoblasts 
by multiplex immunofluorescence, in 17 surgical “OSNew” biopsies at diagnosis. The Dis-
covery ULTRA (Roche, Ventana Medical Systems, Innovation Park Drive Tucson, Arizona 
85755 USA) was used to automate the staining procedure. After dewaxing, the tissue 
slides were heat pre-treated using a CC1 (pH8) buffer (05424569001, Roche). The slides 
were then stained for multiplex immunofluorescence using the RUO Discovery Universal 
procedure (v0.00.0370) in a 4-step protocol with sequential denaturation (CC2 buffer 
(pH6), at 100 °C, 05279798001, Roche) after each step. The fluorochrome sequence recom-
mendations were respected [55]. Tissue slides were subsequently incubated using the pri-
mary antibodies CD8 (clone C8/144B, M7103, Agilent technologies, Santa Clara, CA, USA) 
at a 1/200 dilution (in Envision Flex diluent (K800621-2, Agilent Technologies, Santa Clara, 
CA, USA)), CD163 (clone MRQ-26, 05973929001, Roche), CD68 (clone KP-1, 05278252001, 
Roche) and SATB2 (clone SATBA4B10, MSK101.05, Diagomics, Blagnac, France) at a dilu-
tion of 1/50 (in Envision Flex diluent (K800621-2, Agilent Technologies)). Targets were 
then linked using the OmniMap anti-rabbit (05269679001, Roche) and OmniMap anti-
mouse (05269652001, Roche) HRP conjugated secondary antibodies. Visualization of the 
different targets was finally established using the Rhodamin6G (07988168001, Roche), 
RED610 (07988176001, Roche), Cy5 (07551215001, Roche) and FAM (07988150001, Roche) 
detection kits. The tissue slides were counterstained using Hoechst 33342 (H21492 (Ther-
mofisher, Waltham, MA, USA), 1/500 in Discovery Diluent (Roche)) and mounted with 
gelatin mounting medium (GG1, Sigma-Aldrich, St Louis, MO, USA). 
4.6. Tumor Annotation and Digital Image Analysis 
Fluorescent stained whole tissue slides of “OSNew” surgical biopsies (n = 17), were 
scanned in 16 bits using the Zeiss AxioScan.Z1 (Carl Zeiss, Oberkochen, Germany) whole-
slide scanner equipped with a Colibri 7 solid-state light source and appropriate filter cu-
bes. To improve our understanding of the OS immune landscape, we quantified tumor-
associated macrophages and CD8+ T-cells by multiplex immunohistochemistry and digi-
tal image analysis in order to reduce subjective/human error. In the context of osteosar-
coma, due to the heterogeneity of pre-analytic treatment of the samples, we were obliged 
to study each case for differential pre-analytic staining variations and to perform an adap-
tive treatment of the output-image for correct threshold setting. Pre-analytic staining var-
iations comprise variable affinity of the Hoechst-counterstain to nuclei, variable back-
ground staining of bone matrix, variable intensity of cell-markers. Areas presenting arte-
facts such as tissue folds, degraded tissue fragments, were excluded from the analysis. 
Initially 20 surgical biopsies were included in the study, 3 of them were excluded for ab-
sence of clear nuclear staining most likely due to an extended decalcification during tissue 
processing. 
Using the HighPlex FL module of the HALO  imaging analysis software (Indica 
Labs, Albuquerque, NM, USA), we studied the OS TME in 2 morphologically distinct tu-
mor regions annotated by a certified pathologist (AGB). These tumor regions were se-
lected based on their osteolytic (OL) and osteoid matrix-rich (OM) morphological charac-
teristics. In total, 240 different OL (83.6%) and 47 OM (16.4%) regions of interest were 
selected. Cells stained with a cytoplasmic/membranous intensity exceeding the settings 
threshold were counted as positive for the full range of staining intensity. Due to the dif-
ferences in bone matrix content of the 2 tumor regions, results were represented as the 
percentage of the cells positive for the defined phenotypes; SATB2+, CD8+, CD163+, 
CD68+ and the CD68+/CD163+, CD68-/CD163+, CD68+/CD163- populations. The cellular 
density for these different phenotypes (Number per mm2) were also recorded. 
4.7. CSF-1R and TRAP Assays in Patient Serum  
The biomarkers (CSF-1R and TRAP) were analyzed in serum at the four previously 
mentioned timepoints (n = 108). The serum was processed, aliquoted and stored at -80°C 
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for further analysis. CSF-1R was assayed in 50 µL (diluted at 1/50) by the Bio-Plex® system 
(Luminex, Bio-Rad, Marnes-la-Coquette, France) using the human magnetic Luminex® 
assays M-CSFR/CD115 (R&D Systems Europe, Lille, France). MicroVue Bone TRAP5b 
ELISA (Quidel, San Diego, CA, USA) was used for TRAP activity analysis in 50 µL of 
serum. For both assays, the procedure was performed according to the manufacturer’s 
protocols. Each target concentration was calculated using, respectively, a 5-parameter and 
4-parameter logistic fit curve generated from the standards.  
4.8. Statistical Analysis 
The data was summarized by frequency and percentage for the categorical variables 
and by median and range for the continuous variable. Links with histological response 
were assessed with the Mann-Whitney U test. Overall Survival was defined as the time 
from inclusion to death from any cause (event) or the last follow-up (censored data). Met-
astatic progression-free survival (MPFS) was defined as the time from inclusion to meta-
static progression or death (event) or the last follow-up (censored data). Patients present-
ing local relapse as first event were censored at this date. 
All the survival rates were estimated by the Kaplan-Meier method, with 95% confi-
dence intervals (CI). Univariable and multivariable analyses, adjusting the effect of bi-
omarkers on clinical prognostic factors, were performed using the Cox proportional haz-
ards model. Univariable analyses have been carried out in each treatment arm (ZA- and 
ZA+). Due to the small number of patients and the exploratory nature of this analysis, no 
multiple testing correction was applied. A two-way repeated measure ANOVA was run 
in order to determine if there were differences in TRAP and CSF-1R concentrations over 
time and treatment. Bonferroni’s adjustments were made to account for multiple testing. 
Two-sided p-values <0.05 were considered statistically significant. All statistical analyses 
were performed using STATA 16.0 software. 
5. Conclusions 
The results of the study show that not only OCs but also macrophages represent a 
target for ZA, explaining its negative impact on OS2006 patient prognosis [11]. ZA treat-
ment might not be appropriate for OS patients for whom osteoid matrix formation is pre-
dominant. The multiplex immunohistochemical study of the OS TME and clear definition 
of the macrophage populations present at diagnosis could re-enforce therapeutic deci-
sions. The fact that we found double stained CD68+/CD163+ macrophages, true bipotent 
cells with undefined polarization, stresses the importance of the balance between macro-
phages and OCs in OS development, progression (Figure 5A) and response to treatment 
(Figure 5B). Those bipotent cells might play a significant role in the protective/harmful 
immune cell balance and thus on the patient response to treatment (proposed model Fig-
ure 5) and could be of interest as therapeutic target in the future. Studying the bipotent 
macrophage cell population in culture models and their polarization under various treat-
ments could help to identify new therapeutic strategies. Our data highlight the im-
portance to examine the OS tumor microenvironment in an attempt to propose the most 
appropriate treatment for OS patients. 




Figure 5. (A) The imbalance of osteoclasts, macrophages and bipotent cells involved in tumoral bone remodeling in Oste-
osarcoma. (B) Inhibitory effect of zoledronic acid (ZA) on both deleterious CD68+/CD163− osteoclasts and protective 
CD68−/CD163+ macrophages in Osteosarcoma. 
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6694/13/3/423/s1, Table S1: Demographic, clinical and histological data of the entire initial OS2006 
patient cohort (n = 124), Table S2: Multivariable biomarker analysis adjusted for prognostic clinical 
factors. No significant correlation is observed between biomarkers analyzed and overall survival 
and metastatic progression free survival. (CD8, CD163, CD68: determined by immunohistochemis-
try; CSF-1R and TRAP: determined in serum.) 
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